Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.

Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit. - Adjuvant chemotherapy (TC) for uterine carcinosarcoma: CS-01

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017212

Enrollment

Registered

2015-04-21

Start date

2005-11-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterine carcinosarcoma

Interventions

Paclitaxel + carboplatin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed uterine carcinosarcoma 2) Patients are required to have had complete or optimal (residual disease < 1 cm) resection, as achieved by hysterectomy with bilateral salpingo-oophorectomy at the least. 3) Eastern Cooperative Oncology Group performance status of 0 to 2. 4) Eligible patients did not receive previous radiotherapy or chemotherapy.

Exclusion criteria

Exclusion criteria: Patients with massive ascites, pleural effusion, or active infectious diseases were excluded.

Design outcomes

Primary

Measure	Time frame
progression-free survival	—

Secondary

Measure	Time frame
overall survival adeverse events	—

Countries

Japan

Contacts

Public ContactHideki Tokunaga

Tohoku University Hospital Department of gynecology

tokunagahideki@med.tohoku.ac.jp022-717-7254

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026